Ilaria Dulcamare, Grazia Scandura, Enrico La Spina, Daniela Cambria, Tatiana Zuppelli, Vincenzo Bramanti, Sebastiano Giallongo, Paolo Fontana, Rosario Giuffrida, Giovanni Li Volti
Multiple myeloma (MM) is a haematological disease characterized by plasma cells malignancy and extramedullary and/or peripheral blood progression with significant patient morbidity, thus representing an urgent clinical need. Besides multiple affected sites, resistance to therapy is strongly limiting current available therapies. The Wilms’ tumour 1 (WT1) gene received particular attention in the last decades due to its role as oncogenic factors in acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia and myelodysplastic syndromes, thus becoming an attractive target for immune therapy in such dismal diseases. Herein, we aimed at reviewing current knowledge on the potential role of WT1 in MM pathogenesis and on its potential role as therapeutic target for MM.
